Geneos Wealth Management Inc. Grows Stock Holdings in AstraZeneca PLC $AZN

Geneos Wealth Management Inc. boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 329.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,196 shares of the company’s stock after buying an additional 59,228 shares during the quarter. Geneos Wealth Management Inc.’s holdings in AstraZeneca were worth $5,394,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Pekin Hardy Strauss Inc. boosted its position in shares of AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock worth $255,000 after acquiring an additional 148 shares in the last quarter. Richardson Financial Services Inc. boosted its holdings in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after purchasing an additional 149 shares in the last quarter. Evergreen Capital Management LLC increased its stake in AstraZeneca by 0.7% in the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock valued at $1,743,000 after purchasing an additional 155 shares during the last quarter. Grimes & Company Inc. raised its holdings in AstraZeneca by 3.0% during the second quarter. Grimes & Company Inc. now owns 5,290 shares of the company’s stock worth $370,000 after purchasing an additional 155 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management lifted its position in shares of AstraZeneca by 5.2% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,174 shares of the company’s stock worth $222,000 after buying an additional 158 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

NASDAQ AZN opened at $89.83 on Monday. The firm has a market cap of $278.60 billion, a P/E ratio of 29.84, a P/E/G ratio of 1.66 and a beta of 0.31. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $94.01. The business’s 50-day moving average price is $87.03 and its 200 day moving average price is $79.22. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The firm had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the prior year, the business earned $2.08 EPS. The firm’s revenue was up 12.0% compared to the same quarter last year. On average, equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

AZN has been the topic of a number of recent analyst reports. HSBC reaffirmed a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a research report on Wednesday. Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group began coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.